Back to search

Poland· PL-100524496

Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris

A emtricitabine, tenofovir alafenamide and rilpivirine product containing emtricitabinum + rilpivirinum + tenofovirum alafenamidum, registered in Poland by Viatris Ltd. The same ATC class is registered in 13 of our 19 countries.

ATC J05AR19

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedEmtricitabine/Rilpivirine/Tenofovir A…ATCJ05AR19REGISTER NO.PL-100524496PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Emtricitabine, tenofovir alafenamide and rilpivirine is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AR19 (emtricitabine, tenofovir alafenamide and rilpivirine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Emtricitabine, tenofovir alafenamide and rilpivirine · ATC J05AR19

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Emtricitabinum + Rilpivirinum + Tenofovirum alafenamidum
Manufacturer
Viatris Ltd
Country
Poland (PL)
ATC code
J05AR19
ATC class
Emtricitabine, tenofovir alafenamide and rilpivirine
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05901797711597

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Emtricitabine, tenofovir alafenamide and rilpivirine in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All emtricitabine, tenofovir alafenamide and rilpivirine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, Odefsey
  • Liechtenstein · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, Odefsey
  • Norway · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, Odefsey

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/18b96abe-79a5-4fed-a4ab-f22d363f6036
GET /v1/drugs/18b96abe-79a5-4fed-a4ab-f22d363f6036?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "200 mg + 25 mg + 25 mg",
  "packaging": "05901797711597 ¦ Rpz ¦ EU/1/25/1966/001 ¦ 163613\n30 tabl. w blistrze\nRpz ¦ EU/1/25/1966/002 ¦ 163614\n90 tabl. w blistrze\nRpz ¦ EU/1/25/1966/003 ¦ 163615\n30 tabl. w blistrze perforowanym\nRpz ¦ EU/1/25/1966/004 ¦ 163616\n90 tabl. w blistrze perforowanym\nRpz ¦ EU/1/25/1966/005 ¦ 163617\n30 tabl. w butelce\nRpz ¦ EU/1/25/1966/006 ¦ 163618\n90 tabl. w butelce",
  "substance": "Emtricitabinum 200 mg + Rilpivirinum 25 mg + Tenofovirum alafenamidum 25 mg",
  "common_name": "Emtricitabinum + Rilpivirinum + Tenofovirum alafenamidum",
  "pl_product_id": "100524496",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about emtricitabine, tenofovir alafenamide and rilpivirine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.